RVTY vs SYNC.L
RVTY: Revvity is a leading health science technology company providing integrated workflows and reagents spanning drug discovery, development, and diagnostic applications across life sciences and diagnostics markets. SYNC.L: A London-listed investment firm that creates and builds pioneering life science companies, with a specialized focus on advanced therapies and oncology.
Side-by-side fundamentals
| Metric | RVTY | SYNC.L | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $108.07 | £1.07 | |
| Market cap as of 2026-08-06 | $12.1B | n/a | |
| P/E as of 2026-08-06 | 53.93 | n/a | |
| PEG as of 2026-08-06 | 5.81 | n/a | |
| Net margin as of 2026-08-06 | +8.2% | n/a | |
| Gross margin as of 2026-08-06 | +55.0% | n/a | |
| Operating margin as of 2026-08-06 | +12.3% | n/a | |
| ROE as of 2026-08-06 | +3.3% | n/a | |
| ROA as of 2026-08-06 | +2.0% | n/a | |
| Debt / equity as of 2026-08-06 | 0.44 | n/a | |
| Revenue growth (YoY) as of 2026-08-06 | +4.0% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -9.3% | n/a | |
| Dividend yield as of 2026-08-06 | +0.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 3 | n/a | |
| Beta as of 2026-08-06 | 1.07 | n/a | |
| 1-year return as of 2026-07-27 close | +4.2% | +10.7% | SYNC.L higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.